What can change in the cannabis market after the end of sanitary authorization of RDC 327?

The Brazilian market for medicinal cannabis is preparing to achieve significant milestones in the coming years, according to the recent release of the 2nd Medicinal Cannabis Yearbook in Brazil, by Kaya Mind, a leader in data and market intelligence in the cannabis, hemp, and derivatives segment.

With notable growth, it is expected that the market will reach the impressive mark of over 1 billion reais in revenue as early as next year. Currently, Brazil has approximately 430,000 patients who generate a substantial sum of R$ 699.4 million, representing increases of 130% and 92%, respectively, compared to the numbers from 2022.

The yearbook also reveals that Brazilian consumers have access to a wide variety of options, with more than 1,700 products available in 25 different pharmaceutical forms. This diverse market is served by 897 companies and 137 patient associations.

Based on the document's projections, the medicinal cannabis market will continue to rise in the coming years. It is forecasted that revenues will exceed R$ 1.014 billion in 2024 and reach over R$ 1.4 billion in 2025.

Free webinar will clarify the regulation of medicinal cannabis in Brazil. Click to find out how to participate. 

A free webinar is scheduled for Thursday, April 4th, at 2:00 PM, with the aim of clarifying the implications of Collegiate Board Resolution (RDC) 327/2019 and discussing the changes that occur after the expiration of the sanitary authorization established in this resolution. The online event will feature renowned experts in the field of health and regulation, who will provide valuable insights on the regulatory scenario of medicinal cannabis in the country. 

"With the expiration of RDC 327, medicinal cannabis products in Brazil will need to be registered as medicines with Anvisa. This involves the preparation of regulatory documents and the conduct of preclinical tests and clinical studies. Since tests take a considerable amount of time to be conducted, companies need to start as soon as possible to be able to keep their products in the market," explains Clarissa Rodrigues, PhD in Health Science and CEO of GRINN.  

Confirmed speakers for the webinar bring with them a wealth of experience and knowledge in the field of health and regulation:

Dr. Alessandra Rabelo: Commercial Director and Generalist Pharmacist, with over 13 years of experience in drug development and clinical research.

Dr. Talita Ferreira: Business Consultant and Biochemical Pharmacist, with a master's degree in Entrepreneurship and a doctorate in Business Economics, bringing a unique perspective on innovation in health.

Dr. Miriana Machado: Pharmacist with master's and doctorate degrees in Cellular and Molecular Biology, with extensive experience in safety assessment of products for regulatory purposes.

Dr. Clarissa Rodrigues: Co-founder and CEO of a company specialized in clinical research, with master's and doctorate degrees in Health Science, and certification in Clinical Evaluation in Toxicology.

These experts will provide a comprehensive view on the regulation of medicinal cannabis in Brazil, offering a broad perspective for professionals in the field and those interested in the topic.